Multi-Cancer Early Detection (MCED), a novel blood test, has successfully screened multiple cancers in 6,662 asymptomatic individuals > 50 years of age as part of a Pathfinder study. The findings were presented at the European Society for Medical Oncology Congress 2022 in Paris. Cancer was detected in about 1% of participants. 71 % of confirmed cases had cancer types for which routine screening is unavailable. The cancer signal was detected in 92 participants, and 35 of them were diagnosed with 36 cancers.
11 different cancer types were detected that have no standard screening. The accuracy of cancer signal origin prediction was 97%, with a false positive rate of < 1%. MCED screening was able to detect more cancers than all US Preventive Services Task Force-recommended standard single cancer screenings combined. When added to standard screening, MCED testing increased the number of…
